Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 343-350

  Ferrandina, G ^a   Scambia, G ^a   Damia, G ^b   Tagliabue, G ^b   Fagotti, A ^a   Benedetti Panici, P ^a   Mangioni, C ^c   Mancuso, S ^a   D'Incalci, M ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Ospedale S Gerando   (Italy)

Author keywords

Glutathione S transferase; Ovarian cancer; Prognosis; Response to chemotherapy

Indexed keywords

CISPLATIN; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031009242     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008247428385     Document Type: Article

References (41)

1. Herod JJO, Eliopoulos AG, Warwick J et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56: 2178-84.
2. Pegram MD, Pietras RJ, Chazin VR et al. Effect of erb-B2 (HER-2/neu) overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Proc Am Ass Cancer Res 1993; 34: A452.
3. Scambia G, Ferrandina G, Marone M et al. nm23 in ovarien cancer: Correlation with clinical outcome and other clinicopalhological and biochemical prognostic parameters. J Clin Oncol 1996; 14: 334-42.
4. Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer 1993; 71: 644-9.
5. Mannervik B. The isozymes of glutalhione transferase. Adv Enzymol 1985; 57: 357-417.
6. Meijer C, Mulder NH, Hospers GAP et al. The role of glulathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 1990; 62: 72-7.
7. Lutzky J, Astor MB, Taub RN et al. Role of glutathione and dependent enzymes in anthracycline-resislant HL60/AR cells. Cancer Res 1989; 49: 4120-5.
8. Black SM, Beggs VD, Hayes JD et al. Expression of human glulathione S-transferase in S cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem J 1990; 268: 309-15.
9. Lewis AD, Hayes JD, Wolf CR. Glulathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: Intrinsic differences and cell cycle erfects. Carcinogenesis 1988; 9(7): 1283-7.
10. Mistry P, Kelland LR, Abel G et al. The relationships between glutalhione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-20.
11. Saburi Y, Nakagawa M, Ono M et al. Increased expression of glulathione s-tranferase gene in cis-diamminedichloroplatinum (II)-resistant variant of a Chinese Hamster ovarian cell line. Cancer Res 1989; 49: 7020-5.
12. Batist G, Tulple A, Sinha BK et al. Overexpression of a novel anionic glutathione transferase in multidrug-resitant human breast cancer cells. J Biol Chem 1986; 261: 15544-9
13. Murphy D, McGown AT, Hall A et al. Glutathionc S-transferase activity and isoenzyme distribution in ovarian tumors biopsies taken before or after cytotoxic chemotherapy. Br J Cancer 1992; 66: 937-42.
14. van der Zee AGJ, van Ommen B, Meijer C et al. Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumors, untreated malignant ovarian tumors, and malignant ovarian tumors after platinum/cyclophosphamide chemotherapy. Br J Cancer 1992; 66: 930-6.
15. Green JA, Robertson LJ, Clark A. H. Glutathione S-transferase expression in benign and malignant ovarian tumors. Br J Cancer 1993; 68: 235-239
16. Hamada S, Kamada M, Furumoto K et al. Expression of glutathione s-transferase-π in human ovarian cancer as an indicator of resistance to chemotheraphy. Gynecol Oncol 1994; 52: 313-9.
17. Kase H, Kodama S, Tanaka K. Expression of glutathione S-transferase π and cisplatin resistance in human ovarian cancer. Int J Gynecol Cancer 1996; 6: 241-5.
18. van der Zee A, Hollema H, Suurmeijer AJH et al. Value of P-glycoprotein. glutathione S-transferase pi, e-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8.
19. Wrigley EC, McGown AT, Buckley H et al. Glutathione S-trans-ferase activity and isoenzyme levels measured by two methods in ovarian cancer, their value as markers of disease outcome. Br J Cancer 1996; 73: 763-9.
20. Ghazal-Aswad S, Hogarth L, Hall AG et al. The relationship between tumor glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian patients. Br J Cancer 1996; 74: 468-73.
21. Rahilly M, Al Nafussi A, Harrison DJ. Distribution of glutathione S-transferase isoenzymes in primary epithelial tumors of the ovary. Int J Gynecol Cancer 1991; 1: 268-74.
22. Smith M, Evans C, Doane-Setzer P, Castro V, Denitrosation of 1,3 bis (2-chlorolthyl)-1-nitrosourea by class mu glutathione translerases and its role in cellular resistance in rat brain tumour cells. Cancer Res 1989; 49: 2621-5.
23. International Federation of Gynecology and Obstetrics. Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263-4.
24. Serov SF, Scully RE. Histological typing of ovarian tumors. In: International Histological Classification of Tumors, Vol. 9. Geneva: World Healh Organizazion 1979.
25. 2) cisplatin-induced neurotoxicity in primary ovarian cancer patients. Cancer Treat Rep 1987; 71: 669-70.
26. Benedetti Panici P, Greggi S, Scambia G et al. Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 1995; 31 (12): 1987-92.
27. Benedetti Panici P, Pierelli L, Scambia G et al. High-dose carboplatin, etoposide, and melphulan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: Nonhaematologic. haematologic toxicities and role of growth factor administration. Br J cancer 1996 (in press).
28. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. No. 48. Geneva: WHO 1979; 16-21.
29. Scambia G, Benedetti Panici P, Battaglia F et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992; 10: 529-35.
30. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-9.
31. EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980; 16: 1513-5.
32. Hanley JA, McNeil BJ. The meaning and the use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
33. Mantel N. Evaluation of survival data and two new rank order statistics arising its consideration. Cancer Chemother Rep 1966; 50: 163-70.
34. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 197-220.
35. Cox DR. Analysis of Binary Data. London: Methuen 1970.
36. Codegoni AM, Broggini M, Pitelli MR et al. Expression of genes of potential importance for the response to chemotherapy and DNA repair in patients with ovarian cancer. Gyn Oncol 1997; 65(1): 130-7.
37. Larsson A, Orrenius S, Holmgren A, Mannervik B (eds). Functions of Glutathione: Biochemical, Physiological, Toxicological and Clinical Aspects. New York; Raven Press 1983.
38. Scambia G, Benedetti Panici P, Ferrandina G et al. Expression of HER-2/neu oncoprotein. DNA-ploidy and S-phase fraction in advanced ovarian cancer. Int J Gynaecol Cancer 1993; 3: 271-8.
39. Moscow JA, Townsend AJ, Goldsmith ME et al. Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci USA 1988; 85: 6518-22.
40. Gilberet L, Elwood LJ, Merino M et al. A pilot study of pi-class glulathione S-transferase expression in breast cancer: Correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993; 11 (1): 49-58.
41. Christen RD, Horn DK, Porter DC et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 1990; 86: 1632-40.